IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway

BACKGROUND: Sorafenib is the standard targeted drug used to treat hepatocellular carcinoma (HCC), but the therapeutic response between individuals varies markedly. Recently, cytokine-based immunotherapy has been a topic of intense discussion in the fight against cancer. The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xiaoyan, Sun, Wei, Chen, Jinglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234789/
https://www.ncbi.nlm.nih.gov/pubmed/30459526
http://dx.doi.org/10.1186/s12935-018-0671-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234789/
https://www.ncbi.nlm.nih.gov/pubmed/30459526
http://dx.doi.org/10.1186/s12935-018-0671-3

Ejemplares similares